Effects of benazepril on cardiac fibrosis in STZ-induced diabetic rats

Acta Cardiologica

Volumn 65, Issue 4, 2010, Pages 431-439

  Li, Qian ^a   Wang, Yi ^a   Sun, Shu Zhen ^a   Tian, Yong Jie ^a   Liu, Ming Hua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

ACE inhibitors; Diabetic cardiomyopathy; Fibrosis; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

BENAZEPRIL; COLLAGEN; GELATINASE A; GLUCOSE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BENZAZEPINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE BLOOD LEVEL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART MUSCLE FIBROSIS; HEART WEIGHT; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; WISTAR RAT; ANALYSIS OF VARIANCE; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; ENZYME IMMUNOASSAY; FIBROSIS; HEART MUSCLE; METABOLISM; ORGAN SIZE; PATHOLOGY; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAINING AND LABELING; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 78049259587     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.65.4.2053902     Document Type: Article

References (34)

1. Korosoglou G, Humpert PM. Non-invasive diagnostic imaging techniques as a window into the diabetic heart: a review of experimental and clinical data. Exp Clin Endocrinol Diabetes 2007; 115: 211-20. (Pubitemid 46762247)
2. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-57. (Pubitemid 39627201)
3. Loganathan R, Bilgen M, Al-Hafez B, Smirnova IV. Characterization of alterations in diabetic myocardial tissue using high resolution MRI. Int J Cardiovasc Imaging 2006; 22: 81-90. (Pubitemid 43372356)
4. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47: 693-700. (Pubitemid 43243087)
5. Tyagi SC, Rodriguez W, Patel AM, Roberts AM, Falcone JC, Passmore JC, Fleming JT, Joshua IG. Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling. J Cardiovasc Pharmacol Ther 2005; 10: 1-10. (Pubitemid 40503637)
6. Hudon-David F, Bouzeghrane F, Couture P, Thibault G. Thy-1 expression by cardiac fibroblasts: Lack of association with myofibroblast contractile markers. J Mol Cell Cardiol 2007; 42: 991-1000. (Pubitemid 46691271)
7. Mori S, Gibson G, McTiernan CF. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model. J Card Fail 2006; 12: 314-25.
8. Lopez B, Gonzalez A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48: 89-96. (Pubitemid 43929208)
9. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004; 9: 43-51.
10. Cleutjens JP. The role of matrix metalloproteinases in heart disease. Cardiovasc Res 1996; 32: 816-21.
11. Lee SW, Song KE, Shin DS, Ahn SM, Ha ES, Kim DJ, Nam MS, Lee KW. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005; 69: 175-9.
12. Bollano E, Omerovic E, Svensson H, Waagstein F, Fu M. Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. Int J Cardiol 2007; 114: 195-201. (Pubitemid 44791509)
13. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM. Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 2005; 46: 426-32. (Pubitemid 41099180)
14. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005; 90: 783-90. (Pubitemid 41406067)
15. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006; 20: 1546-8. (Pubitemid 44943825)
16. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99: 801-15.
17. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, Cheng TH. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004; 61: 159-68. (Pubitemid 38056692)
18. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001; 116: 417-25. (Pubitemid 32202907)
19. Papadopoulos DP, Economou EV, Makris TK, Kapetanios KJ, Moyssakis I, Votteas VE, Toutouzas PK. Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction. Drugs Exp Clin Res 2004; 30: 55-65. (Pubitemid 38917674)
20. Zierhut W, Studer R, Laurent D, Kästner S, Allegrini P, Whitebread S, Cumin F, Baum HP, de Gasparo M, Drexler H. Left ventricular wall stress and sarcoplasmic reticulum Ca(2 +)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade. Cardiovasc Res 1996; 31: 758-68. (Pubitemid 126334405)
21. Hu QW, Liu GT. Effects of bicyclol on dimethylnitrosamine-induced liver fibrosis in mice and its mechanism of action. Life Sci 2006; 79: 606-12.
22. Ueshima K, Shibata M, Suzuki T, Endo S, Hiramori K. Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase-1, and effects of magnesium pretreatment on reperfusion injury. Magnes Res 2003; 16: 120-6. (Pubitemid 37386926)
23. Li J, Schwimmbeck PL, Tschope C, Leschka S, Husmann L, Rutschow S, Reichenbach F, Noutsias M, Kobalz U, Poller W, Spillmann F, Zeichhardt H, Schultheiss HP, Pauschinger M. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002; 56: 235-47. (Pubitemid 35223494)
24. Reddy HK, Tjahja IE, Campbell SE, Janicki JS, Hayden MR, Tyagi SC. Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation. Mol Cell Biochem 2004; 264: 183-91.
25. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2006; 65: 40-51. (Pubitemid 43805861)
26. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 2004; 18: 828-35. (Pubitemid 38544501)
27. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 2001; 69: 527-42.
28. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Böhm M, Pauschinger M, Schultheiss HP, Tschöpe C. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2008; 103: 319-27.
29. Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA. Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows Arch 2005; 446: 369-78. (Pubitemid 40674843)
30. Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol 2005; 4: 9.
31. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
32. Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 2002; 34: 1435-42.
33. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2004; 286: C779-784. (Pubitemid 38543805)
34. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78: 195-201. (Pubitemid 40979958)